電連技術(300679.SZ):控股子公司通過高新技術企業認定
格隆匯 2 月 1日丨電連技術(300679.SZ)公佈,公司控股子公司恆赫鼎富(蘇州)電子有限公司(“恆赫鼎富”)於近日收到由科學技術部火炬高技術產業開發中心出具的《關於江蘇省2020 年第一批高新技術企業備案的覆函》(國科火字〔2021〕39 號),獲悉恆赫鼎富獲得江蘇省2020 年高新技術企業資質,證書編號為:GR202032005884。
恆赫鼎富系首次被認定為高新技術企業。根據國家相關規定,恆赫鼎富自通過高新技術企業認定起連續三年享受高新技術企業的相關税收優惠政策,即按15% 的税率繳納企業所得税。該税收優惠政策對公司及恆赫鼎富後續經營產生一定的積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.